微透析技术进行痰瘀互结型冠心病大鼠的证治药动学研究探索

朱黎霞; 梁东辉

doi:10.13422/j.cnki.syfjx.2014160119

您当前的位置：

首页 >

文章列表页 >

微透析技术进行痰瘀互结型冠心病大鼠的证治药动学研究探索

药物代谢 | 更新时间：2024-01-04

- 微透析技术进行痰瘀互结型冠心病大鼠的证治药动学研究探索
- Syndrome and Treatment Pharmacokinetics Research and Exploration Based on Microdialysis Method about Coronary Heart Disease with Syndrome of Intermin-gled Phlegm and Blood Stasis
- 中国实验方剂学杂志 2014年20卷第16期页码：119-123
- 作者机构：
- 作者简介：
- 基金信息：
  
  国家自然科学基金项目（81302882）
- DOI：10.13422/j.cnki.syfjx.2014160119
  中图分类号： R285.5
- 纸质出版日期：2014
- 稿件说明：
移动端阅览
朱黎霞, 梁东辉. 微透析技术进行痰瘀互结型冠心病大鼠的证治药动学研究探索[J]. 中国实验方剂学杂志, 2014,20(16):119-123.

ZHU Li-xia, LIANG Dong-hui. Syndrome and Treatment Pharmacokinetics Research and Exploration Based on Microdialysis Method about Coronary Heart Disease with Syndrome of Intermin-gled Phlegm and Blood Stasis[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(16): 119-123.
朱黎霞, 梁东辉. 微透析技术进行痰瘀互结型冠心病大鼠的证治药动学研究探索[J]. 中国实验方剂学杂志, 2014,20(16):119-123. DOI： 10.13422/j.cnki.syfjx.2014160119.

ZHU Li-xia, LIANG Dong-hui. Syndrome and Treatment Pharmacokinetics Research and Exploration Based on Microdialysis Method about Coronary Heart Disease with Syndrome of Intermin-gled Phlegm and Blood Stasis[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(16): 119-123. DOI： 10.13422/j.cnki.syfjx.2014160119.

摘要

目的：进行基于“实时、活体、动态、微创”特征的微透析采样技术的证治药动学探索性研究。方法： SD大鼠通过连续7周给予高脂饲料并结扎冠状动脉左前降支复制痰瘀互结型冠心病模型。正常组和痰瘀互结型冠心病组、丹参素高、低剂量组，每组各6只大鼠，提取物中丹参素的给药量为分别为25.3，50.6 mg·kg-1，进行正常和冠心病大鼠的证治药动学研究。单次灌胃给药后，血液微透析法活体、动态采样，高效液相色谱法检测微透析样品丹参素的浓度，采用非房室模型处理获得药动学参数。结果：模型组大鼠血清总胆固醇（TC）、甘油三酯（TG）、血清肌酸磷酸激酶（CK）升高，高、中、低切变率下全血黏度升高，与正常组差异具有统计学意义（P<0.01）。获取了不同机能状态下丹参素的药动学特征。和正常组相比，痰瘀互结型冠心病大鼠丹参素达峰浓度（Cmax）增加，但无统计学意义；达峰时间（Tmax）缩短，零阶矩（AUC）、一阶矩曲线下面积（AUMC）增加，和正常组相比，结果具有统计学意义（P<0.05）。结论：本研究模式可为类似证治药动学研究做借鉴。

Abstract

Objective: The syndrome and treatment pharmacokinetics model was carried out based on the ‘real-time

dynamic

minimally invasive

in vivo’ microdialysis sampling method. Method: The intermin-gled phlegm and blood stasis syndrome coronary heart disease SD rats model was replicated by feeding with high fat diet for 7 weeks combined with left anterior descending branch coronary artery ligation. The normal group and the model group were was divided into high and low dose group with 6 rats in each group

the extract of Danshensu dosage was respectively 25.3

50.6 mg· kg-1. The pharmacokinetics study was carried out on normal and coronarg heatt disease(CHD) rats by intragastric administration of different dose. The Danshensu concentration of microdialysis samples were detected with HPLC and the pharmacokinetic parameters was obtained using noncompartmental model. Result: The results showed that serum total cholesterol(TC)

triglyceride(TG)

creatine phosphokinase(CK) in the model group increased

blood viscosity of high

medium and low shear also increased. The results had highly statistically significant differences compared with the normal group(P<0.01).The results showed that Danshensu peak concentration increases

but without statistical significance

the peak time shorten

area under the curve(AUC) and area under the first moment curve(AUMC) increases in CHD rats comparing with the normal group

the results were statistically significant(P<0.05). Conclusion: This study can be the reference for the similar research mode.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

丹参胶囊的系统稳定性考察

大鼠在体单向肠灌流法进行丹参素、丹酚酸B的肠吸收研究

首乌方对帕金森病模型大鼠血液和纹状体细胞外液左旋多巴药代动力学影响的研究